Skip Navigation

European Heart Journal 2002 23(8):627-632; doi:10.1053/euhj.2001.2940
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baird, S.H.
Right arrow Articles by Wilson, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baird, S.H.
Right arrow Articles by Wilson, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction

S.H. Baird, I.B.A. Menownf1, S.J. Mcbride, T.G. Trouton and C. Wilson

Department of Cardiology, Antrim Area Hospital, Antrim, N. Ireland, U.K.

revised July 24, 2001; accepted July 25, 2001

Abstract

Aims To compare the efficacy and safety of low molecular weight heparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.

Methods and Results Three-hundred patients receiving fibrinolytic therapy following acute myocardial infarction were randomly assigned to low molecular weight heparin as enoxaparin (40mg intravenous bolus, then 40mg subcutaneously every 8h, n=149) or unfractionated heparin (5000U intravenous bolus, then 30000U.24h–1, adjusted to an activated partial thromboplastin time 2–2·5x normal, n=151) for 4 days in conjunction with routine therapy. Clinical and therapeutic variables were analysed, in addition to use of enoxaparin or unfractionated heparin, to determine independent predictors of the 90-day composite triple end-point (death, non-fatal reinfarction, or readmission with unstable angina). The triple end-point occurred more frequently in patients receiving unfractionated heparin rather than enoxaparin (36% vs. 26%;P =0·04). Logistic regression modelling of baseline and clinical variables identified the only independent risk factors for recurrent events as left ventricular failure, hypertension, and use of unfractionated heparin rather than enoxaparin. There was no difference in major haemorrhage between those receiving enoxaparin (3%) and unfractionated heparin (4%).

Conclusion Use of enoxaparin compared with unfractionated heparin in patients receiving fibrinolytic therapy for acute myocardial infarction was associated with fewer recurrent cardiac events at 90 days. This benefit was independent of other important clinical and therapeutic factors.

Key Words: Low molecular weight heparin, unfractionated heparin, fibrinolytic therapy, acute myocardial infarction

f1 Correspondence: Dr I. B. A. Menown, MD, MRCP, Department of Cardiology, Antrim Area Hospital, Antrim BT41 2RL, N. Ireland, U.K.

References

  1. Antman EM, Giugliano RP, Gibson CM. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation. 1999;99:2720–2732[Abstract/Free Full Text]
  2. Lancet. 1992;339:753–770[Web of Science][Medline]
  3. Mahaffey KW, Granger CB, Collins R. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996;77:551–556[CrossRef][Web of Science][Medline]
  4. Granger CB, Becker R, Tracy RP. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. J Am Coll Cardiol. 1998;31:497–505[Abstract/Free Full Text]
  5. N Engl J Med. 1993;329:1615–1622[Abstract/Free Full Text]
  6. Berdan LG, Kleiman NS, Woodlief LH. Physicians' use of heparin following thrombolytic therapy: an international perspective. J Thromb Thrombolysis. 1997;4:415–423[CrossRef][Medline]
  7. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911–921[Abstract/Free Full Text]
  8. Antman EM, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608[Abstract/Free Full Text]
  9. N Engl J Med. 1993;329:673–682[Abstract/Free Full Text]
  10. Simoons, ML, Acute myocardial infarction – streptokinase (AMI-SK) study. Preliminary Results
  11. Frostfeldt G, Ahlberg G, Gustafsson G. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction—a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol. 1999;33:627–633[Abstract/Free Full Text]
  12. Molhoek GP, Knudtson M, Lundergan CF. A randomized comparison of low molecular weight heparin (enoxaparin) and unfractionated heparin to t-PA thrombolysis and aspirin (HART II). Eur Heart J. 2000;21:600
  13. Cohen, M, Antithrombotic Combination Using Tirofiban and Enoxaparin (ACUTE II): Preliminary Results
  14. Kereiakes DJ, Grines C, Fry E. Abciximab-enoxaparin interaction during percutaneous coronary intervention: results of the NICE 1 and 4 trials. J Am Coll Cardiol. 2000;35:92[CrossRef]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
D. J. Quinlan and J. W. Eikelboom
Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction
Arch Intern Med, June 22, 2009; 169(12): 1163 - 1164.
[Full Text] [PDF]

Home page
 ChestHome page
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 708S - 775S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. A. Murphy, C. M. Gibson, D. A. Morrow, F. Van de Werf, I. B. Menown, S. G. Goodman, K. W. Mahaffey, M. Cohen, C. H. McCabe, E. M. Antman, et al.
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
Eur. Heart J., September 1, 2007; 28(17): 2077 - 2086.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Circulation, December 20, 2005; 112(25): 3855 - 3867.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Part 8: Stabilization of the Patient With Acute Coronary Syndromes
Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110.
[Full Text] [PDF]

Home page
 CirculationHome page
Part 5: Acute Coronary Syndromes
Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. S Kalus and L. R Moser
Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction
Ann. Pharmacother., March 1, 2005; 39(3): 481 - 491.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 549S - 575S.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. C. Wong, R. P. Giugliano, and E. M. Antman
Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention
JAMA, January 15, 2003; 289(3): 331 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C.P. Cannon
A reply
Eur. Heart J., October 2, 2002; 23(20): 1633 - 1634.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
C.P. Cannon
Enoxaparin in ST elevation MI--a bright future
Eur. Heart J., April 2, 2002; 23(8): 591 - 592.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baird, S.H.
Right arrow Articles by Wilson, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baird, S.H.
Right arrow Articles by Wilson, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?